Clinical Trial

Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan for Aesthetic Improvement

Study acronym: HA35-ORAL
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 13, 2026 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of high-dose oral 70 kDa hyaluronan (HA35) for aesthetic improvement. Eligible participants will receive 5 g oral HA35 once daily on an empty stomach for 40 consecutive days. The primary objectives are to assess changes in facial and body subcutaneous fullness, inflammatory erythema, facial vitality, and body weight. Safety, gastrointestinal tolerability, and additional exploratory outcomes will be evaluated throughout the intervention period. This is a minimal-risk, oral, non-pharmacological supportive care intervention.
Trial Details
NCT Number NCT07583108
Lead Sponsor Nakhia Impex LLC
Conditions Facial Subcutaneous Fullness, Subcutaneous Fat Accumulation, Facial Inflammatory Erythema, Dull Skin, Facial Vitality Impairment, Body Weight Management
Enrollment 30 participants
Start Date 2026-05-20
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-13